Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christof Scheid

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
The Lancet. Haematology|November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialHartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Blood Cancer Journal|October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myelomaJia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
Advances in Therapy|November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMentHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
Journal of Clinical Medicine|June 24, 2022
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM StudyAnna Waszczuk-Gajda, Olaf Penack, Giulia Sbianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
The Lancet. Haematology|February 1, 2024
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trialElias K Mai, Hartmut Goldschmid, Kaya Miah, et al.
The Lancet. Haematology|November 3, 2022
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialHartmut Goldschmidt, Elias K Mai, Uta Bertsch, et al.
Leukemia|March 25, 2022
LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myelomaMaria-Victoria Mateos, Katja Weisel, Valerio De Stefano, et al.
Blood Cancer Journal|October 20, 2025
Prospective systematic classification of causes of death in the course of multiple myelomaJia Xiang Jin, Britta Besemer, Büsranur Yilmaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 18, 2012
Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trialPieter Sonneveld, Ingo G H Schmidt-Wolf, Bronno van der Holt, et al.
Advances in Therapy|November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMentHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
Journal of Clinical Medicine|June 24, 2022
Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM StudyAnna Waszczuk-Gajda, Olaf Penack, Giulia Sbianchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 9, 2024
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 TrialElias K Mai, Uta Bertsch, Ema Pozek, et al.
Leukemia|June 3, 2024
CD8<sup>+</sup> CD28<sup>-</sup> regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III studyKatharina Kriegsmann, Gigi Nu Hoang Quy Ton, Mohamed H S Awwad, et al.
Pageof 20